Summit Therapeutics Inc.

Good morning, everyone, and welcome to the Summit Therapeutics second quarter 2023 earnings call. Please note that this call is being recorded. All lines have been placed on listen-only mode at this time. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question, please press star followed by the number one on your telephone keypad. To withdraw your question, again, press star one. I would now like to turn today's call over to Dave Gancars. Please go ahead.

Good morning and thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Today's call is being simultaneously webcast and an archived replay will also be made available later today on our website, www.smmtc.com. Joining me on the call today is Bob Duggan, our Chairman of the Board and Co-Chief Executive Officer. Dr. Marquis Zongani, our Co-Chief Executive Officer and President, Ankur Dhingra, our Chief Financial Officer, and Dr. Alan Yang, who I'm happy to introduce as our new Head of Research and Development. Welcome, Alan. Before we get started, I would like to note that some statements made by our management team and some responses to questions that we make today may be considered forward-looking statements based on our current expectations. Submit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these statements. Risks and Uncertainties. Submit undertakes no obligation to update these forward-looking statements except as required by law. Following comments from Bob, McKee, and Onker, we will take questions. And with that, I will turn the call over to Bob. Thank you, Dave.

Good morning, everyone. Thank you for joining us today. I'd like to say a few words about what our amazing team has accomplished. Then I will hand it over to McKee to add more color. And then Onker will provide some updates regarding our financial positions and outlook. In terms of blending high-quality work output with speed and efficiency if you can match the skills of Team Summit. In January 2023, we closed our transaction with the KESO to in-license Ibonissimab, and since that time, we have launched two Phase III clinical trials, both with the registrational intent and, most importantly, in alignment with our Summit mission statement to improve the quality of the lives of patients with all due speed. As I spoke about last quarter, at the end of our business development process in 2022, we chose Avanissimab to be the foundation of Summit moving forward, and Acaso chose Team Summit as the caretaker of their premier pipeline product candidate in the major Western markets. Team Summit takes full responsibility for maximizing the beneficial impact of Avanissimab in the United States, Europe, and Japan, all the while making significant difference for the betterment in the lives of patients we treat. We take full responsibility for developing our Benizumab in the United States, Canada, Europe, and Japan in order to make that significant difference in patients' lives. This is our commitment. We continue to build upon the established and continuing success and patient results created by Acesto. Our team has made multiple visits to Acesto in the past few months, and spent meaningful time in person with the KESO's leadership over the past year, including our most recent trip to China during the second quarter. As we propel our collaboration forward, we continue to work together to achieve the best possible results and realize the potential of abonissimat. Our clearly aligned missions, each of which focus on the needs of patients and improving patient lives, allow for coordinated actions within our partnership as we curate the future of our business map. In a highly positive manner, Team ACESSO has changed the paradigm in patient care in specific cancers and continues to make this progress every day. Continuing with this trend, Team Summit has one multi-regional phase three clinical trial underway, and we are about to dose our first patient in a second multi-regional phase three trial. We have chosen to work with ACESSO in each trial. not because we had to, but because we wanted to, and it's in the best interest of all stakeholders. And they have collaborated fully in working with us. In our second phase three trial for first-line squamous cell carcinoma of the lung, they have their own trial in a similar setting specific to China. But alongside that, they've chosen to participate and enroll patients to participate in the summit-led multi-regional trial as well. This demonstrates their dedication to the partnership their commitment to becoming a worldwide biopharmaceutical company, and their desire to bring Avanisimab to as many patients as possible, as quickly as possible. We chose the right partner, and we believe they chose a pretty good one as well. And we're excited about what intent, our intent to accomplish with Avanisimab in the coming couple of years. With that, I would like to hand it over to McKee to provide additional context as to our accomplishments and next steps. McKee?